Coordination and Support Action BrainHealth The CSA BrainHealth addresses the biomedical, economic and societal challenges of diseases and decreased mental health in Europe, aiming for collaborative solutions in prevention, diagnosis and therapies. The overarching goal is to foster and promote global brain health and enhance the well-being of individuals with mental disorders or neurological [...]

The EU-funded BRAINTEASER project aims to bring Artificial Intelligence home for a better care of amyotrophic lateral sclerosis and multiple sclerosis.

PRIME is an EU-funded project (H2020-EU.3.1.1. - Understanding health, wellbeing and disease) and states that insulin signalling not only affects the body (e.g., diabetes and obesity) but also the brain (e.g., Alzheimer’s disease, autism and obsessive-compulsive disorders).

Full project name: HetERogeneous sEmantic Data integratIon for the guT-bRain interplaY Funding Programme and Grant Agreement number: Horizon Europe, GA No. 101137074 Duration: 48 months Consortium: Universita Degli Studi di Padova, Sirma Ai Ead, Surf Bv, Stichting Radboud Universitair Medisch Centrum, Observa Associazione, Fundacion Empresa Universidad Gallega, Universita Degli Studi Di Torino, Aalborg Universitet, [...]

The “FuEl ThE bRaiN In healtThY aging and agE-relateD diseases” ETERNITY will contribute to the strengthening of the European innovation capacity by training a new generation of researchers with experience and full understanding of the requirements of academia, pharmaceutical and food supplement companies, and the society.

Full project name: Nanoplatforms for Neuroscience Funding Programme and Grant Agreement number: HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Duration: 36 months Short description: NeuroNanotech will train eleven researchers to tackle one of the major challenges in Europe’s ageing population - neurological diseases. The ability to monitor and modulate neural activity using interfaces has enabled [...]

AGORA is an ERA-NET NEURON-funded project aiming to improve the effectiveness of therapy of chronic neuropathic pain (CNP) and rate of responders in future clinical trials delivering the treatment to targeted subgroups of patients.

Rethinking Schizophrenia Rethinking Schizophrenia is a research-driven project offering tangible policy changes to improve the lives of people living with schizophrenia across Europe. It challenges the status quo and refreshes the European policy debate on people living with schizophrenia and encourages multi-stakeholder-driven policy. The project falls under #BeyondTheVoices campaign. [...]

Rethinking Migraine in times of COVID-19 Rethinking Migraine in times of COVID-19 is a research-driven project offering tangible policy changes to improve the lives of people living with migraine across Europe. It challenges the status quo and refreshes the European policy debate on people living with migraine, recognises the consequences of the burdens [...]

Rethinking Alzheimer's Disease Rethinking Alzheimer's disease (AD) is a research-driven project offering policy recommendations to make tangible changes with the aim to improve the lives of people living with Alzheimer’s disease across Europe. About Alzheimer's Disease Alzheimer’s disease is a neurodegenerative disease that progresses in stages, beginning with a long silent phase [...]